Developing a collection of clinical, imaging and biologic specimens to identify biological
markers of Parkinson’s risk, onset and progression
Research Question:
Does collecting data from participants with Parkinson's Disease allow identification
of markers of disease?
Basic Study Information
Purpose:
The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational,
multi-center natural history study to assess progression of clinical features, digital
outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression
in study participants with manifest PD, prodromal PD, and healthy controls.
The overall goal of the study is to identify markers of disease progression for use
in
clinical trials of therapies to reduce progression of PD disability.
Location: University of Rochester
Study Reference #: STUDY00005089
Lead Researcher (Principal Investigator)
Lead Researcher:
Ruth Schneider
Study Contact Information
Study Coordinator: Anisha Singh
Phone: (585) 341-7515
Email: Anisha_Singh@URMC.Rochester.edu
Additional Study Details
Study Details:
Individuals ages 30 years and older who do not have a diagnosis of Parkinson's Disease
are currently eligible to participate. We are currently recruiting only healthy controls
and prodromal participants.
Trial Not Found
The study you are looking for is not active at this time.
Return to Search